A Second Dose of Measles Vaccine (MV) in the Second Year of Life

Child Mortality Clinical Trial

Official title:
Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life

Status Completed

Clinical Trial Summary

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02943681
Study type	Interventional
Source	Bandim Health Project
Contact
Status	Completed
Phase	N/A
Start date	October 2016
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04716712` - Infant Mortality Reduction by the Mass Administration of Azithromycin	Phase 4
Completed	`NCT02233127` - Birth Cohort in Rahimyar Khan, Pakistan	N/A
Completed	`NCT03676751` - MORDOR II Burkina Faso: Longitudinal Trial	Phase 4
Completed	`NCT04617626` - Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire	N/A
Completed	`NCT03367832` - South African Paediatric Surgical Outcomes Study (SAPSOS)	N/A
Recruiting	`NCT00656591` - Community-Based Interventions for Infant Health in Nepal	Phase 1
Recruiting	`NCT04235816` - Improving Care Through Azithromycin Research for Infants in Africa	Phase 3
Recruiting	`NCT05016895` - REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire	N/A
Completed	`NCT01571765` - MNCH Programming in Southwest Uganda Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA	N/A